TPN and the Gut: How It Affects Intestinal Function

September 4, 2025

Introduction to TPN and Digestive Health

Total Parenteral Nutrition (TPN) is a complex medical intervention that allows individuals, especially those with severe digestive conditions, to meet their nutritional needs by bypassing the digestive tract entirely. While life-saving, TPN can profoundly affect intestinal function and overall gut health. This article provides an insightful exploration of TPN's impacts on the gut, including its physiological implications, effects on liver function, and the delicate balance of gut microbiota.

The Essentials of Total Parenteral Nutrition (TPN)

Definition and Purpose of TPN

Total parenteral nutrition (TPN) is a method of delivering essential nutrients directly into the bloodstream through an intravenous (IV) catheter. This approach is crucial for patients who are unable to adequately absorb nutrients through their digestive system, often due to conditions like short bowel syndrome (SBS), post-surgical complications, or gut diseases. TPN helps meet metabolic needs and supports growth, especially in vulnerable populations like infants and children suffering from severe gastrointestinal issues.

Nutrients Delivered via TPN

TPN solutions are meticulously formulated to provide a balance of all necessary nutrients, including:

  • Proteins: For tissue repair and growth.
  • Carbohydrates: To supply energy.
  • Fats: Essential fatty acids and additional calories.
  • Vitamins and Minerals: To support various body functions and prevent deficiencies.

Why TPN Bypasses the Gut

TPN bypasses the gut to overcome malabsorption issues that hinder nutrient uptake. This direct delivery method ensures that all nutrients get utilized by the body without the digestive processes that can be obstructed by certain medical conditions. While it provides immediate nutritional support, healthcare providers must closely monitor patients for potential complications, including infections from the IV line and liver dysfunction associated with long-term TPN use.

Does TPN Bypass the Gut?

Total parenteral nutrition (TPN) does indeed bypass the gut entirely, as it delivers essential nutrients directly into the bloodstream through an intravenous catheter. This method is crucial for individuals, particularly children, who cannot properly absorb nutrients through their digestive system due to various medical conditions. TPN solutions are tailored to meet individual nutritional needs and include proteins, carbohydrates, fats, vitamins, and minerals. While TPN can provide necessary nutrition, it also carries risks such as infections and liver disease, requiring careful management and monitoring by healthcare professionals. Overall, TPN serves as a vital nutritional support system for those unable to rely on traditional feeding methods.

Intestinal Failure and the Role of TPN

What is intestinal failure and how does TPN help?

Intestinal failure is a condition where the intestines are unable to properly digest food and absorb the essential nutrients and fluids needed to maintain health. This situation often arises from severe conditions such as short bowel syndrome (SBS) , characterized by the surgical removal of large portions of the small intestine, leading to malabsorption issues.

For patients suffering from intestinal failure, the administration of Total Parenteral Nutrition (TPN) is a crucial lifeline. TPN supplies all necessary nutrients directly into the bloodstream through a catheter, bypassing the digestive system entirely. This method allows patients to receive adequate calories and nutrients intravenously, essential for their survival.

However, while TPN can sustain life over extended periods, its long-term use poses significant risks. Complications such as bone disorders, infections , and liver disease can arise. The management of intestinal failure involves a multifaceted approach: dietary adjustments, medications, and in specific cases, intestinal transplantation may be needed.

It's important to note that the causes of intestinal failure may differ between pediatric and adult patients, requiring tailored treatment strategies and careful monitoring to enhance their quality of life.

Management strategies

To effectively manage patients on TPN, healthcare providers focus on regular assessments of their nutritional status and gastrointestinal health. Implementing maintenance strategies such as supplementing with glutamine can support gut function, while probiotics and prebiotics might restore microbiota balance, mitigating some of the adverse effects associated with TPN. Regular monitoring and adjustments to TPN formula compositions can help minimize the chances of complications, ensuring better outcomes for these vulnerable patients.

Effects of TPN on Intestinal Function and Permeability

Intestinal Mucosal Atrophy

Total parenteral nutrition (TPN) is known to cause intestinal mucosal atrophy, which is a significant concern, particularly in patients requiring long-term nutritional support. This condition leads to decreased villus height and surface area in the intestines, which ultimately impairs nutrient absorption and gut function. Studies highlight that enteral nutrition (EN) is preferable in protecting against atrophy, as nourishment via the gastrointestinal tract can stimulate mucosal health more effectively than TPN, which bypasses normal digestive processes.

Increased Intestinal Permeability

Patients on TPN often experience increased intestinal permeability, a condition that allows microbes and endotoxins to enter the bloodstream. This translocation is associated with parenteral nutrition-associated liver disease (PNALD), intensifying concerns about liver health. Compromised gut barrier function can worsen inflammation and lead to systemic complications. Reports suggest that despite the known dysregulation of gut microbiota and increased inflammatory markers in TPN patients, the actual incidence of bacterial translocation remains comparable to those receiving enteral feeding.

Comparison with Enteral Nutrition

When comparing TPN to enteral nutrition, several studies indicate that EN is more beneficial in promoting intestinal integrity. Enteral feeding not only stimulates the intestinal mucosa but also helps retain gut function and microbiota diversity. For example, in a study of patients post-gastrectomy, those receiving EN showed quicker recovery of markers associated with mucosal integrity than their TPN counterparts. This suggests that continuing with enteral nutrition, when possible, could greatly improve outcomes for individuals at risk of complications related to TPN.

Gut Microbiota Alterations Due to TPN

Changes in gut microbiota composition

Total parenteral nutrition (TPN) significantly alters the gut microbiota, leading to notable changes in its composition. Patients on TPN have shown an increase in Proteobacteria and a decrease in Firmicutes. These shifts in microbial populations can have undesirable effects on both intestinal and liver health. For instance, decreased bacterial diversity is commonly associated with gastrointestinal disorders.

Impact on gut and liver health

The dysregulation of gut microbiota caused by TPN can contribute to serious health complications. Increased intestinal permeability, often seen in TPN patients, allows bacteria and endotoxins to translocate, aggravating liver injury and contributing to parenteral nutrition-associated liver disease (PNALD). Additionally, compromised gut barrier functions may lead to inflammatory conditions and negatively affect nutrient absorption, posing further risks to the patient's health.

Therapeutic interventions

To combat the adverse effects of TPN on gut microbiota, several therapeutic strategies are being explored. Supplementation with short-chain fatty acids (SCFAs) has demonstrated potential in enhancing gut integrity and reducing inflammation. Furthermore, fecal microbiota transplantation (FMT) has emerged as a promising option for restoring healthy gut flora in patients experiencing PNALD, showing positive outcomes in similar gastrointestinal conditions. These interventions may be crucial in improving the overall health of TPN-dependent patients.

Consequences of TPN on Liver Function

How does TPN affect the liver?

Total Parenteral Nutrition (TPN) can significantly affect the liver, especially with long-term use. While transient liver reactions may occur, these can often be managed by adjusting the TPN formula. Over time, patients may develop parenteral nutrition-associated liver disease (PNALD), impacting up to 50% of individuals after five to seven years on TPN. Factors such as the composition of the TPN solution, the absence of enteral feeding, and underlying medical conditions contribute to the risk of liver disease.

Development of Parenteral Nutrition-Associated Liver Disease (PNALD)

PNALD is characterized by various liver pathologies that stem from dysregulation in bile acids and short-chain fatty acids (SCFAs), which are crucial for liver health. Increased intestinal permeability due to compromised gut barrier function, a common issue in TPN patients, can lead to microbial translocation, exacerbating liver injury and PNALD development. It's essential to recognize that alterations in gut microbiota, such as increased Proteobacteria and decreased Firmicutes, correlate with adverse effects on both intestinal and liver health.

Mechanisms and contributing factors

The detrimental effects of TPN on liver function include changes in mucosal structure and microbiota composition, alongside increased gut inflammation as indicated by elevated inflammatory markers like myeloperoxidase activity. Supplementation strategies, such as SCFA and fiber addition, have shown promise in restoring gut integrity and potentially alleviating PNALD. Effective monitoring of bile acids and gut microbiota can provide insights into the patient's liver health.

Monitoring liver health in TPN users

Healthcare providers closely monitor patients receiving TPN to mitigate the risks associated with liver function decline and manage complications effectively. Routine assessments may include liver enzyme levels and markers of inflammation to ensure timely interventions. The incorporation of enteral nutrition, when safe and feasible, can be beneficial to support liver health by stimulating the intestines, which may help reduce the incidence of PNALD.

Gut Barrier Integrity and TPN Implications

Mechanisms Leading to Compromised Gut Barrier

Total parenteral nutrition (TPN) plays a critical role in the management of patients with intestinal failure, but it comes with significant challenges to gut health. One of the primary mechanisms by which TPN compromises gut barrier integrity is through alterations in the gut microbiota. Studies have observed an increase in potentially harmful Proteobacteria and a decrease in beneficial Firmicutes among TPN patients, which can exacerbate conditions like parenteral nutrition-associated liver disease (PNALD).

Additionally, TPN is associated with increased intestinal permeability and microbial translocation, leading to a heightened risk of infections and liver injury. The absence of enteral feeding means that the gut mucosa is not adequately stimulated, which can result in smooth muscle atrophy and a weakened barrier function over time.

Role of SCFAs and Therapeutic Potential of Supplementation

Supplementation of short-chain fatty acids (SCFAs) has shown promise in mitigating some of the adverse effects associated with TPN. SCFAs are vital for maintaining gut integrity and reducing inflammation, potentially promoting a healthier gut environment. Experimental studies suggest that SCFA supplementation can help restore gut function, indicating a viable direction for future therapeutic interventions in TPN patients.

FMT as a Possible Intervention

Fecal microbiota transplantation (FMT) emerges as another innovative approach to restore gut health in patients suffering from the complications of TPN. By re-establishing a balanced microbiome, FMT has demonstrated potential benefits in enhancing gut barrier function and combating dysbiosis. Although primarily studied in conditions like inflammatory bowel disease, the implications for patients on TPN could be substantial, warranting further exploration to harness FMT’s therapeutic effects.

Bowel Movements and Gastrointestinal Symptoms in TPN Patients

Does TPN affect bowel movements?

People on Total Parenteral Nutrition (TPN) can still have bowel movements, although their frequency may be reduced. TPN is designed for patients whose intestines are not functioning properly, allowing the gut to rest. However, the bypassing of the digestive system means that some patients experience less regular bowel movements.

Diarrhea and other GI symptoms

Diarrhea is a common issue in TPN patients, often attributed to several factors including excessive glucose, high-fat content, or hyperosmolar solutions in TPN formulations. These can irritate the intestinal lining, leading to gastrointestinal disturbances. Additionally, imbalances in gut flora may promote harmful microorganisms, further contributing to diarrhea.

Management of GI complications

Managing gastrointestinal symptoms in TPN patients requires close monitoring and potential dietary adjustments. For instance, adjustments in the composition of TPN solutions, like reducing excessive sugars or fats, can mitigate diarrhea. The incorporation of nutrients like glutamine and fiber could also help in maintaining gut integrity and reducing symptoms. Evaluating the overall nutrient delivery system ensures that complications associated with bowel movements are addressed effectively.

Symptom Cause Management Strategy
Frequency of BM Reduced intestinal function Nutritional management
Diarrhea Excess glucose, irritants Adjust TPN composition
Bacterial overgrowth Dysbiosis due to TPN Probiotics, prebiotics supplementation

Understanding TPN-Related Complications in Pediatric Populations

Children with short bowel syndrome

Total parenteral nutrition (TPN) is often lifesaving for children suffering from short bowel syndrome (SBS), which arises from significant intestinal resection. These patients struggle with nutrient absorption, necessitating TPN, which delivers essential nutrients directly into the bloodstream. However, prolonged reliance on TPN may lead to complications such as gut mucosal atrophy and dysbiosis of gut microbiota, ultimately affecting their overall health.

Specific challenges in neonates

Preterm infants, in particular, face unique challenges when on TPN due to their underdeveloped digestive systems. They are at risk for severe complications like necrotizing enterocolitis (NEC) and liver disease. In this fragile population, TPN must be closely monitored to ensure adequate caloric delivery while minimizing adverse gastrointestinal effects such as diarrhea or bacterial overgrowth.

Strategies to manage complications

Managing TPN complications requires a multi-faceted approach. Introducing dietary components such as fiber can support gut integrity and reduce bacterial translocation. Furthermore, considering the use of probiotics or prebiotics may improve gut microbial balance and potentially mitigate adverse outcomes. Continuous assessment and adjustment of TPN can enhance nutritional benefits while minimizing risks, critical for the growth and health of pediatric patients.

Potential Therapies to Mitigate TPN Side Effects

Prebiotics, Probiotics, and Synbiotics

Given the perturbations in gut microbiota linked to total parenteral nutrition (TPN), implementing prebiotics and probiotics presents a promising avenue. Prebiotics, like oligosaccharides, can promote the growth of beneficial gut bacteria, while probiotics introduce live beneficial microorganisms. Synbiotics , which combine both, might optimize gut health, potentially restoring microbiota diversity often compromised by TPN.

Glutamine and Fiber Supplementation

Glutamine supplementation has shown considerable promise for patients on TPN. Research indicates it may enhance gut integrity and immune function, reducing bacterial translocation. Moreover, incorporating fiber into TPN formulations helps maintain intestinal integrity, thereby lessening the incidence of diarrhea and supporting mucosal health. These dietary adjustments provide essential nutrients that might alleviate some adverse gastrointestinal effects of TPN.

Research and Future Directions

More studies are crucial to evaluate the effectiveness of these interventions thoroughly. Future research should aim to establish optimal dosages of prebiotics, probiotics, glutamine, and fiber within TPN regimens. Investigating their combined effects in clinical settings will be instrumental in formulating comprehensive strategies to enhance gut health and improve outcomes for individuals on long-term TPN.

Comparing TPN with Enteral Nutrition

Benefits of enteral over parenteral feeding

Enteral nutrition (EN) offers significant advantages over total parenteral nutrition (TPN). The presence of nutrients in EN stimulates the intestinal mucosa, which promotes gut health and function. In contrast, TPN, which bypasses the digestive system entirely, can lead to complications such as intestinal mucosal atrophy due to the lack of luminal nutrients. EN has been shown to maintain a healthier gut microbiome, reducing the risks associated with dysbiosis that often accompany TPN.

Impact on mucosal integrity

TPN is associated with a decrease in mucosal integrity as indicated by reductions in diamine oxidase (DAO) activity—a marker of intestinal barrier function. In studies where patients underwent either EN or TPN, those receiving EN exhibited quicker recovery rates for mucosal integrity. This suggests that the physiological benefits of enteral feeding play a crucial role in preserving gut architecture compared to TPN, which can contribute to complications such as increased intestinal permeability.

Recovery rates and clinical outcomes

Research indicates that patients on enteral feeding experience better clinical outcomes over time. For example, in a cohort of post-gastrectomy patients, recovery of mucosal function was more pronounced in those receiving EN compared to TPN. Furthermore, while both feeding methods can have complications, the overall risk of gastrointestinal disturbances, including diarrhea, is lower in the EN group. These findings support the preference for enteral nutrition when feasible, as it promotes more favorable recovery rates and improves the overall gut health of the patient.

Concluding Thoughts on TPN and Gut Health

TPN remains an essential intervention for individuals with severe intestinal dysfunction, offering a lifeline to patients unable to derive nutrition from conventional methods. However, its impacts on gut health span beyond merely nutritional support, warranting cautious monitoring and innovative therapeutic strategies to address arising complications. Ongoing research and development in the field are crucial in optimizing TPN therapies, ensuring they not only sustain life but also enhance its quality by minimizing adverse gastrointestinal outcomes.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More